argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-02-25 08:13 |
argenx to Present at Cowen 40th Annual Health Care Conference
|
English | 26.9 KB | ||
| 2020-02-20 08:36 |
argenx to report full year 2019 financial results and fourth quarter business u…
|
English | 34.0 KB | ||
| 2020-01-09 09:32 |
argenx Provides Strategic Outlook Advancing Late-Stage Pipeline Towards ‘argenx…
|
English | 74.9 KB | ||
| 2019-12-11 07:53 |
argenx announces publication of efgartigimod Phase 2 primary immune thrombocyto…
|
English | 38.5 KB | ||
| 2019-12-09 08:27 |
argenx Announces Receipt of First Milestone Payment under Janssen Collaboration…
|
English | 41.8 KB | ||
| 2019-11-26 08:31 |
argenx Announces Upcoming Investor Events
|
English | 35.7 KB | ||
| 2019-11-25 14:57 |
argenx announces results of Extraordinary General Meeting of Shareholders
|
English | 32.1 KB | ||
| 2019-11-13 08:33 |
argenx announces closing of global offering
|
English | 47.1 KB | ||
| 2019-11-08 08:32 |
argenx announces full exercise of underwriters’ option to purchase additional A…
|
English | 46.9 KB | ||
| 2019-11-07 08:48 |
argenx announces launch of proposed global offering
|
English | 58.0 KB | ||
| 2019-11-07 08:39 |
argenx raises $484 million in gross proceeds in a global offering
|
English | 54.9 KB | ||
| 2019-11-06 18:32 |
argenx to Present Data at Upcoming 61st American Society of Hematology (ASH) An…
|
English | 37.1 KB | ||
| 2019-10-30 08:36 |
argenx to Participate in Upcoming Investor Conferences
|
English | 33.4 KB | ||
| 2019-10-24 08:28 |
argenx reports third quarter 2019 financial results and provides business update
|
English | 241.0 KB | ||
| 2019-10-14 08:21 |
Invitation to the extraordinary shareholders’ meeting
|
English | 30.0 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
